Short Bowel Syndrome Market Size, Share, Trends, Growth, Production, Consumption, Revenue and Forecast 2020 - 2027

Published Date : Dec 2020 | No. of Pages : 200 Pages | Category : Healthcare

The global short bowel syndrome market size surpassed at US$ 568 Mn in 2019 and expected to reach US$ 4.6 billion by 2027 with a CAGR of 26% from 2020 to 2027. The global market is driven by increase in awareness and acceptance of the short bowel syndrome treatment.

Demand for Glucagon-like Peptide-2 (GLP-2) for Treatment of Short Bowel Syndrome

In terms of drug class, the glucagon-like peptide-2 (GLP-2) is expected to be the leading segment of the short bowel syndrome market during the forecast period. The only available GLP-2 analog in the market for the treatment of short bowel syndrome is Gattex/Revestive. The strong growth of this segment can be attributed to the increase in prescriptions for the Gattex therapy, rise in the number of patients on Gattex therapy, and high cost of the drug. This drug is commercially available in North America and selected countries in Europe, including the U.K., Germany, France, Italy, Spain, and Nordics. Furthermore, this compound was awarded orphan drug status in Japan in 2014 and is in Phase III clinical trials.

Gattex has been awarded the orphan drug exclusivity until 2019 in the U.S. and until 2024 in Europe, which prevents the launch of drugs based on the same active particle in these regions. This would enhance the revenue generated by the sale of Gattex/Revestive and strengthen its market share. The market for GLP-2 analog is projected to grow, owing to its ability to reduce the patients’ dependence on parenteral nutrition.

Growth Hormone Approved for Treatment of Short Bowel Syndrome

Growth hormone approved for the treatment of short bowel syndrome is Zorbtive. The growth hormone drug class segment is anticipated to expand at a meagre CAGR, owing to its patent expiry. Furthermore, the glutamine approved for the treatment of short bowel syndrome, NutreStore, is administered to patients who are on specialized nutrition, in conjunction with the growth hormone approved for this indication.

The market for other drugs used for the treatment of short bowel syndrome is expected to record modest growth. This can be attributed to their usage in the treatment of symptoms associated with short bowel syndrome. Other drugs used include anti-diarrheal (to treat the primary symptom of short bowel syndrome, diarrhea), proton pump inhibitors (used to treat gastric acid secretions), and H-2 receptor blockers. These drugs are administered to a patient, along with nutritional support.

Increase in Clinical Trials or Pipeline Drugs for Short Bowel Syndrome Treatment to Propel Market

Strong pipeline drugs for short bowel syndrome are anticipated to provide tremendous growth opportunities for the market in the near future. Pipeline drugs such as Zealand Pharma’s Glepaglutide (ZP1848), a long acting GLP-2 analog for short bowel syndrome, is in phase III clinical trials, results of which is expected in 2021. Pipeline drugs for short bowel syndrome act as a driver for the short bowel syndrome market. The late stage clinical development pipeline consists of several first-in-class drugs that are effective and safe for short bowel syndrome patients. Once these drugs are launched, the short bowel syndrome market is expected to witness growth at a significant rate, owing to better efficacy than their current counterparts.

North America to Lead Short Bowel Syndrome Market

North America was the dominant region in the short bowel syndrome market and is expected to lead the market during the forecast period. The robust growth of the short bowel syndrome market in North America can be mainly attributed to the increase in prescriptions of Gattex therapy in the U.S. In addition, growth hormone and glutamine have been approved for the treatment of short bowel syndrome only in the U.S.

Pre-marketing strategies adopted by short bowel syndrome market players to create awareness about the syndrome and its treatment also contribute to the market expansion in North America. For instance, prior to the launch of Gattex, NPS Pharmaceuticals (now Shire acquired by Takeda Pharmaceutical Company Limited), utilized an unbranded educational website, ShortBowelSupport.com, to raise awareness among patients, families, and healthcare professionals. Europe is expected to be the second major region in the short bowel syndrome market, owing to the approval of Revestive in the region and increase in awareness among people.

Key Segments

  • In terms of drug class, the short bowel syndrome market has been categorized into glucagon-like peptide-2 (GLP-2), growth hormone, glutamine, and others. Parenteral nutrition reduces the risk of malnutrition and dehydration and gradually, the patients can be weaned off parenteral nutrition based on intestinal adaptation.
  • The primary aim of the treatment of SBS patients includes restoring fluid and electrolyte balance. Glucagon-like Peptide-2 (GLP-2) approved for the indication is administered to the patients who are on parenteral nutrition. It is an antisecretory, transit modulating, and intestinotrophic agents that enable the treatment of SBS. Intestinotrophic effects of GLP-2 are mediated by increase in the proliferation of intestinal crypt cells; increase in villous height in jejunum, duodenum, and ileum; and enterocyte proliferation in the jejunal crypt.
  • This GLP-2 aided increase in intestinal cell mass aids in mucosal growth, enhances activities of intestinal brush-border enzymes, delays the gastric transit, and increases the intestinal capacity for nutrient absorption
  • In addition, the GLP-2 analog differs from the natural GLP-2 by a single amino acid, where an alanine is replaced by a glycine. This structural difference increases the half-life of the GLP-2 analog to two hours as compared to seven minutes half-life of the natural GLP-2.
  • GLP-2 analog is also resistant to degradation by dipeptidyl peptidase-IV (DDP-IV). These features make it the most preferred mode of treatment available for SBS patients. This is likely to drive the short bowel syndrome market during the forecast period.
  • The market size and forecast for each of the segments have been provided in terms of US$ Mn from 2017 to 2027, along with their respective CAGRs for the forecast period from 2019 to 2027, considering 2019 as the base year

Regional Outlook

  • Geographically, the short bowel syndrome market has been segmented into four major regions: North America (U.S. and Canada), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Japan, and Rest of the World (India, China, Australia & New Zealand, Brazil, and Middle East)
  • The market size and forecast for each of these regions and the mentioned countries/sub-regions have been provided for the period from 2017 to 2027, along with their respective CAGRs for the forecast period from 2020 to 2027, considering 2019 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

  • The report also profiles following mentioned major players in the short bowel syndrome market based on various attributes such as company overview, financial overview, treatment types, business strategies, and recent developments. The companies include
    • Shire plc (Takeda Pharmaceutical Company Limited)
    • Zealand Pharma A/S
    • Sancilio & Company, Inc.
    • OxThera
    • Nutrinia Ltd.
    • Ardelyx, Inc.
    • Emmaus Life Sciences, Inc.
    • GLyPharma Therapeutic, Inc. (Pfizer Inc.)
    • Merck KGaA
    • Naia Pharmaceuticals, Inc.

Market Segmentation

By Drug Class

    • Glucagon-like Peptide-2 (GLP-2)
    • Growth Hormone
    • Glutamine
    • Others

By Region

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • U.K.
      • France
      • Spain
      • Italy
      • Rest of Europe
    • Japan
    • Rest of the World

 

Scope of the Report

The report on the global short bowel syndrome market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the market during the forecast period from 2020 to 2027. The report provides the revenue of the short bowel syndrome market for the period 2017–2027, considering 2020 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the short bowel syndrome market for the forecast period. The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global short bowel syndrome market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts have also employed a combination of top-down and bottom-up approaches to study various phenomena in the short bowel syndrome market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study. Additionally, the report sheds light on the changing competitive dynamics in the short bowel syndrome market. These indices serve as valuable tools for existing market players as well as for entities interested in participating in the short bowel syndrome market. The next section of the short bowel syndrome report highlights the USPs, which include drivers & restraints impact analysis, value chain analysis; short bowel syndrome disease overview, short bowel syndrome epidemiology, rare diseases prevalence, overview of clinical trials for short bowel syndrome, qualitative analysis of glp-2 product, research & development cost analysis, impact analysis of clinical trials cost on orphan drugs, cost analysis of therapies using orphan drugs, approved U.S. orphan indications, 1983–2015, approved European orphan indications, 2019, pricing analysis, orphan drugs – price volume analysis, justifications for the high cost of Gattex & Teduglutide, regulations scenario assessment, flow chart guide to determine eligibility for standard orphan designation in Australia, impact analysis of regulatory scenario assessment, comparative analysis of orphan drug policies, orphan drug manufacturing companies, acquisitions timeline, and SWOT analysis.

The report analyzes the short bowel syndrome market in terms of drug class and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2027 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the short bowel syndrome market.

Key Questions Answered in Short Bowel Syndrome Market Report

  • What is the sales/revenue generated by different short bowel syndrome (SBS) across all the regions during the forecast period?
  • What are the major drivers, restraints, and opportunities in the market?
  • Which region is set to expand at the fastest CAGR during the forecast period?
  • Which segment will have the highest revenue globally in 2027 and which product will expand at the fastest CAGR during the forecast period?

Research Objectives and Research Approach

The comprehensive report on the short bowel syndrome market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the short bowel syndrome market. It is followed by market introduction, market dynamics, and an overview of the short bowel syndrome market, which includes TMR analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the short bowel syndrome market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into small sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

Revenue generated by key short bowel syndrome market manufacturers has been mapped to ascertain the size of the short bowel syndrome market in terms of value. The forecast presented here assesses the total revenue generated by dermatome devices. In order to provide an accurate forecast, we initiated by sizing up the current short bowel syndrome market with the help of the parent market.

The report also delves into the competitive landscape of the short bowel syndrome market. Key players operating in the short bowel syndrome treatment market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the short bowel syndrome treatment market report.

Table of Contents

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. Market Dynamics Analysis and Trends

5.1. Market Dynamics

5.1.1. Market Drivers

5.1.2. Market Restraints

5.1.3. Market Opportunities

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining power of suppliers

5.2.2. Bargaining power of buyers

5.2.3. Threat of substitute

5.2.4. Threat of new entrants

5.2.5. Degree of competition

Chapter 6. Competitive Landscape

6.1.1. Company Market Share/Positioning Analysis

6.1.2. Key Strategies Adopted by Players

6.1.3. Vendor Landscape

6.1.3.1. List of Suppliers

6.1.3.2. List of Buyers

Chapter 7. Global Short Bowel Syndrome Market, By Drug Class

7.1. Short Bowel Syndrome Market, by Drug Class Type, 2020-2027

7.1.1. Glucagon-like Peptide-2 (GLP-2)

7.1.1.1. Market Revenue and Forecast (2016-2027)

7.1.2. Growth Hormone

7.1.2.1. Market Revenue and Forecast (2016-2027)

7.1.3. Glutamine

7.1.3.1. Market Revenue and Forecast (2016-2027)

7.1.4. Others

7.1.4.1. Market Revenue and Forecast (2016-2027) 

Chapter 8. Global Short Bowel Syndrome Market, Regional Estimates and Trend Forecast

8.1. North America

8.1.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.1.2. U.S.

8.1.3. Rest of North America

8.1.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2. Europe

8.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2.2. UK

8.2.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2.3. France

8.2.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.2.4. Rest of Europe

8.2.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3. APAC

8.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.2. India

8.3.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.3. China

8.3.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.4. Japan

8.3.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.3.5. Rest of APAC

8.3.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4. MEA

8.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.2. GCC

8.4.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.3. North Africa

8.4.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.4. South Africa

8.4.4.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.4.5. Rest of MEA

8.4.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.5. Latin America

8.5.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.5.2. Brazil

8.5.2.1. Market Revenue and Forecast, by Drug Class (2016-2027)

8.5.3. Rest of LATAM

8.5.3.1. Market Revenue and Forecast, by Drug Class (2016-2027)

Chapter 9. Company Profiles

9.1. Shire plc (Takeda Pharmaceutical Company Limited)

9.1.1. Company Overview

9.1.2. Product Offerings

9.1.3. Financial Performance

9.1.4. Recent Initiatives

9.2. Zealand Pharma A/S

9.2.1. Company Overview

9.2.2. Product Offerings

9.2.3. Financial Performance

9.2.4. Recent Initiatives

9.3. Sancilio & Company, Inc.

9.3.1. Company Overview

9.3.2. Product Offerings

9.3.3. Financial Performance

9.3.4. Recent Initiatives

9.4. OxThera

9.4.1. Company Overview

9.4.2. Product Offerings

9.4.3. Financial Performance

9.4.4. Recent Initiatives

9.5. Nutrinia Ltd.

9.5.1. Company Overview

9.5.2. Product Offerings

9.5.3. Financial Performance

9.5.4. Recent Initiatives

9.6. Ardelyx, Inc.

9.6.1. Company Overview

9.6.2. Product Offerings

9.6.3. Financial Performance

9.6.4. Recent Initiatives

9.7. Emmaus Life Sciences, Inc.

9.7.1. Company Overview

9.7.2. Product Offerings

9.7.3. Financial Performance

9.7.4. Recent Initiatives

9.8. GLyPharma Therapeutic, Inc. (Pfizer Inc.)

9.8.1. Company Overview

9.8.2. Product Offerings

9.8.3. Financial Performance

9.8.4. Recent Initiatives

Chapter 10. Research Methodology

10.1. Primary Research

10.2. Secondary Research

10.3. Assumptions

Chapter 11. Appendix

11.1. About Us

11.2. Glossary of Terms


Featured Research Reports

  • Featured Research Reports

    Women’s Digital Health Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2021-2030

    Read more...
  • Featured Research Reports

    Intravascular Ultrasound Devices Market (By Product: IVUS Consoles and IVUS Catheters; By Application, By End User: Hospitals, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2030

    Read more...
  • Featured Research Reports

    Intravascular Ultrasound Devices Market (By Product: IVUS Consoles and IVUS Catheters; By Application, By End User: Hospitals, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2030

    Read more...
  • Featured Research Reports

    Minimally Invasive Surgery Market (By Procedure, Disorder Type, End User: Hospitals, Ambulatory Surgical Centers, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2028

    Read more...
  • Featured Research Reports

    Minimally Invasive Surgery Market (By Procedure, Disorder Type, End User: Hospitals, Ambulatory Surgical Centers, Clinics, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook and Forecast 2021 - 2028

    Read more...